Krankenhaus Der Barmherzigen Schwestern Wien Betriebsgesellschaft mbH
- Address
- Seilerstaette 4, 4020 Vienna, Austria
Neoplasms
The department is conducting advanced studies on multiple myeloma, evaluating novel immunotherapy combinations for patients who are not eligible for transplant. The goal is to improve disease‑free survival and deepen molecular response.
- Combination immunotherapy with targeted antibodies
- Treatment strategies for transplant‑ineligible patients
- Assessment of minimal residual disease (MRD) status
Researchers at Krankenhaus Der Barmherzigen Schwestern Wien are aiming to set new standards for frontline therapy in blood cancers.
Male Urogenital Diseases
A focused trial addresses acute radiation proctitis in men with prostate carcinoma, testing an 8‑week rectal budesonide regimen against placebo to reduce symptom severity.
- Rectal anti‑inflammatory treatment
- Double‑blind, placebo‑controlled design
- Improvement of CTCAE grading for proctitis
The clinic’s urologic oncology team seeks faster relief for patients undergoing radiotherapy.
Digestive System Diseases
While the primary focus is on urogenital and hematologic conditions, the site also explores therapies relevant to digestive system diseases, particularly radiation‑induced bowel injury.
- Management of radiation‑related gastrointestinal toxicity
- Symptom control and quality‑of‑life outcomes
- Integration of supportive care measures
This broader research aligns with the department’s commitment to comprehensive patient care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 11 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Bluesky Immunotherapies GmbH1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krankenhaus Der Barmherzigen Schwestern Wien Betriebsgesellschaft mbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2 | Celgene Corp. | Phase III | Not Recruiting | Jan 2023 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 2 | Unknown | 2022-11-14 | 2023-01-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.